CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03454451 |
|
Recruitment Status :
Active, not recruiting
First Posted : March 6, 2018
Last Update Posted : August 3, 2022
|
Sponsor:
Corvus Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Corvus Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | December 2025 |